Stay updated on IL-2 Combo for Refractory Checkpoint Blockade Clinical Trial
Sign up to get notified when there's something new on the IL-2 Combo for Refractory Checkpoint Blockade Clinical Trial page.

Latest updates to the IL-2 Combo for Refractory Checkpoint Blockade Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page was updated to Revision v3.4.2 and the government funding lapse notice was removed; no core trial information, eligibility criteria, or patient-facing content were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedStatus updated to Active, not recruiting, and results have been posted with key outcomes (ARR, ORR, DCR, PFS). The page now includes linked study documents (Protocol and Statistical Analysis Plan) and updated dates, enrollment, and locations.SummaryDifference4%

- Check28 days agoChange DetectedAdded a glossary toggle and updated capitalization for QC-related labels and revision text; these changes are cosmetic and do not affect study content or user tasks.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; this update appears to be metadata only with no substantive changes to the study content or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded the Locations section and California as a study location. Updated the page to revision v3.3.3 and removed the earlier California Locations entry and the HHS Vulnerability Disclosure link.SummaryDifference0.2%

- Check77 days agoChange DetectedDeleted the last known status entry for Megan Daly, MD, University of California, Davis, including the date (2023-04) and verification note.SummaryDifference0.4%

Stay in the know with updates to IL-2 Combo for Refractory Checkpoint Blockade Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IL-2 Combo for Refractory Checkpoint Blockade Clinical Trial page.